News and Trends 23 Nov 2022 Tevogen Bio to investigate T cell therapy in long Covid Tevogen Bio is set to study the potential therapeutic use of its investigational Covid-19 T cell therapy, TVGN-489, in long Covid. The finding that none of the patients in the TVGN 489 proof-of-concept (POC) trial, treated for their initial Covid infection, developed long Covid to date is leading Tevogen to explore the potential of TVGN […] November 23, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Startup Scout 21 Nov 2022 Osivax is designing future-proof influenza and Covid vaccines Viruses causing influenza and COVID-19 continually evolve to escape our vaccine protections. The French firm Osivax is developing vaccines that are harder for the viruses to evade. Many life-saving vaccines have been developed and approved to protect against viral infections including COVID-19 and influenza. Commercially available vaccines typically activate the production of antibodies against fragments […] November 21, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2022 Immorna cleared for mRNA-based Covid-19 vaccine study U.S. biotech company Immorna says the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to conduct a phase 1/2 multi-center study of JCXH-221, a lipid nanoparticle (LNP) complexed broadly protective mRNA vaccine against SARS-CoV-2 infection and diseases. The goal of the multi-center study is to assess the safety and immunogenicity […] November 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2022 Novavax’ COVID-19 vaccine gets expanded authorization for booster in adults Novavax, Inc., a U.S-based biotechnology company announced today (November 18) that Health Canada has granted expanded authorization for Covid-19 vaccine Nuvaxovid. The vaccine NVX-CoV2373 for active immunization to prevent the disease caused by severe acute respiratory syndrome (SARS-CoV-2) as a homologous booster in adults aged 18 and older. “Canadians now have access to our […] November 18, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Sanofi and GSK Covid-19 booster vaccine approved by European Commission Sanofi and GSK’s Covid booster vaccine has been approved in Europe. After the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for VidPrevtyn Beta, the vaccine was approved by the European Commission, as a booster for the prevention of Covid-19 in adults 18 years of age and older. […] November 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2022 Does covid vaccination boost cancer treatment? Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. It was feared that vaccination against Covid-19 could reduce the success of cancer treatment or cause severe side effects. However, a recent study by the universities of Bonn, Germany, and Shanxi, China, say this isn’t the case. According […] November 8, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2022Beyond Biotech podcast 21: CanSinoBIO, HTID, Longevity Science Foundation This week, we have three interviews, and four guests. We chat with Pierre Corneille VP of the HTFC, which is responsible for HealthTech Innovation Days; Sergey Jakimov, co-founder and managing partner of LongeVC and the Longevity Science Foundation’s CEO Lisa Ireland; and Pierre Morgon, executive vice president of CanSinoBIO. We also have our weekly contribution […] November 4, 2022 Share WhatsApp Twitter Linkedin Email
News and Trends 3 Nov 2022 Virax Biolabs introduces flu, Covid-19 and RSV rapid test kits Rapid test kits that can accurately identify infections related to respiratory syncytial virus (RSV), influenza and Covid-19 can deliver results in 15 minutes. UK-based Virax Biolabs, a biotech company focused on the prevention, detection and diagnosis of viral diseases announced today (November 3) the distribution of a tripe virus antigen rapid test kit has been […] November 3, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Sponsored by ACROBiosystems 3 Nov 2022 Impacting vaccine development: COVID-19 and its implications for the future of vaccines The development of COVID-19 vaccines was an unprecedented achievement at a time of urgent medical need. We explore the novel technology platforms that went into their development and consider their long-term impact on vaccine research. Ever since the first vaccine against smallpox in the late 1700s, vaccines have gained a reputation as a critical tool […] November 3, 2022 - 8 minutesmins - By Sudha Sundaram Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 Meletios Therapeutics wins €5.2M European Commission funding for SARS research Meletios Therapeutics, a French biotech company, announced today (November 2) that it has been named one of 75 winners of the European Innovation Council (EIC) Accelerator program and will receive €5.2 million ($5.1 million) in funding from the European Commission. The company specializes in the research and development of antiviral treatments and says the funding […] November 2, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2022 The Native Antigen Company expands range of Omicron antigens to include BA.5 variant The Native Antigen Company today (November 2) announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant. The company, part of LGC Clinical Diagnostics, is a supplier of reagents enabling research into vaccines and diagnostics for emerging endemic infectious diseases. The new range of RBD (receptor binding domain) antigens […] November 2, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2022 Inotrem study for the treatment of critically ill COVID-19 patients meets endpoints Inotrem has announced positive results for ESSENTIAL, its phase II clinical trial in COVID-19 patients hospitalized in critical care units and experiencing acute respiratory distress. The French clinical stage biotech company specializes in immunotherapies for acute and chronic inflammatory syndromes. The announcement was made at the European Society of Intensive Care Medicine’s Annual Congress, held […] October 26, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email